Botanix Pharmaceuticals Limited (ASX: BOT)
Health Care · Pharmaceuticals · AU
AU$0.02
-9.09% today · -87.1% 1Y
Botanix Pharmaceuticals Limited (ASX: BOT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $39.20M and employs 11 people.
Over the last twelve months the share price has lost 87.1%, trading between 0.02 and 0.17.
Tweenvest scores Botanix Pharmaceuticals Limited across four factors: quality 26/100, value 50/100, growth 100/100. Its strongest factor is growth.
BOT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $39.20M
- Revenue (TTM)
- $14.62M
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 0.86
- 52-week high
- AU$0.17
- 52-week low
- AU$0.02
- Avg volume (3M)
- —
- Shares outstanding
- 2.73B
- Employees
- 11
- Next earnings
- —
About Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
- ISIN
- AU000000BOT2
- Founded
- 1984
- Listed since
- Jan 31, 1988
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.